- Home
- SCNI
as 11-15-2024 4:00pm EST
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.
| Founded: | 2003 | Country: | Israel |
| Employees: | N/A | City: | JERUSALEM |
| Market Cap: | 3.5M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 12.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.23 - $8.92 | Next Earning Date: | 11-29-2024 |
| Revenue: | $284,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Scinai Immunotherapeutics Ltd. News
SCNI Breaking Stock News: Dive into SCNI Ticker-Specific Updates for Smart Investing
PR Newswire
18 days ago
Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024
PR Newswire
2 months ago
Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies
PR Newswire
3 months ago
Scinai Regains Full Compliance with Nasdaq Listing Requirements
PR Newswire
3 months ago
Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000
PR Newswire
3 months ago
Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder
PR Newswire
3 months ago
Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23
PR Newswire
3 months ago
Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity
PR Newswire
4 months ago
Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb
Compare SCNI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SCNI Scinai Immunotherapeutics Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.